Inhibiting NF-KB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure activity relationship, and co-crystal structuresLi, K., McGee, L.R., Fisher, B., Sudom, A., Liu, J., Rubenstein, S.M., Anwer, M.K., Cushing, T.D., Shin, Y., Ayres, M., Lee, F., Eksterowicz, J., Faulder, P., Waszkowycz, B., Plotnikova, O., Farrelly, E., Xiao, S.H., Chen, G., Wang, Z.
(2013) Bioorg Med Chem Lett 23: 1238-1244
- PubMed: 23374866
- DOI: https://doi.org/10.1016/j.bmcl.2013.01.012
- Primary Citation of Related Structures:
- PubMed Abstract:
The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described. Our work began with an HTS hit, imidazopyridinyl pyrimidinamine 1. We utilized homology modeling and conformational analysis to optimize the indole scaffold leading to the discovery of novel and potent conformationally constrained inhibitors such as compounds 25 and 28. Compounds 25 and 31 were co-crystallized with NIK kinase domain to provide structural insights.
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA. email@example.com